ROZEREM

LOE Approaching

ramelteon

NDAORALTABLET
Approved
Jul 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
52

Mechanism of Action

Melatonin Receptor Agonists

Pharmacologic Class:

Melatonin Receptor Agonist

Clinical Trials (5)

NCT05414864Phase 4Terminated

Insomnia Prevalence and Treatment Impact on Systemic Hypertension

Started May 2022
5 enrolled
InsomniaHypertension
NCT02669082Phase 4Completed

The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy

Started May 2017
26 enrolled
InsomniaMajor Depressive Disorder
NCT01685151Phase 3Withdrawn

A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder

Started Sep 2012
0
Bipolar Disorder
NCT01677182Phase 3Terminated

Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder

Started Aug 2012
535 enrolled
Bipolar Disorder
NCT01467713Phase 3Terminated

Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder

Started Dec 2011
642 enrolled
Bipolar Disorder